Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 4/1999

01-08-1999 | ORIGINAL ARTICLE

Plasma pharmacokinetics and tissue distribution in CD2F1 mice of Pc4 (NSC 676418), a silicone phthalocyanine photodynamic sensitizing agent

Authors: Merrill J. Egorin, Eleanor G. Zuhowski, Dorothy L. Sentz, Jason M. Dobson, Patrick S. Callery, Julie L. Eiseman

Published in: Cancer Chemotherapy and Pharmacology | Issue 4/1999

Login to get access
Metadata
Title
Plasma pharmacokinetics and tissue distribution in CD2F1 mice of Pc4 (NSC 676418), a silicone phthalocyanine photodynamic sensitizing agent
Authors
Merrill J. Egorin
Eleanor G. Zuhowski
Dorothy L. Sentz
Jason M. Dobson
Patrick S. Callery
Julie L. Eiseman
Publication date
01-08-1999
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 4/1999
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s002800050979

Other articles of this Issue 4/1999

Cancer Chemotherapy and Pharmacology 4/1999 Go to the issue

ORIGINAL ARTICLE

A multi-centre randomized phase II study of nolatrexed versus doxorubicin in treatment of Chinese patients with advanced hepatocellular carcinoma

ORIGINAL ARTICLE

Cytotoxicity and neurocytotoxicity of new marine anticancer agents evaluated using in vitro assays

ORIGINAL ARTICLE

Comparative cytotoxicity and pharmacokinetics of antimelanoma immunotoxins containing either natural or recombinant gelonin

ORIGINAL ARTICLE

Investigation of the major human hepatic cytochrome P450 involved in 4-hydroxylation and N -dechloroethylation of trofosfamide

ORIGINAL ARTICLE

Acquired resistance to O 6-benzylguanine plus chloroethylnitrosoureas in human breast cancer

ORIGINAL ARTICLE

Drug retention and distribution after intratumoral chemotherapy with fluorouracil/epinephrine injectable gel in human pancreatic cancer xenografts
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits